{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:26:52Z","timestamp":1793424412696,"version":"4.5.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:p>\n                    Cystic fibrosis (CF) is a genetically inherited disorder characterized by a wide range of clinical manifestations and genetic variations. This study focuses on the genetic and molecular epidemiology of CF in the Russian population, utilizing data from the national CF registry. The birth prevalence of CF in Russia has been analyzed over a span of years, revealing variations in frequency. The study delves into the genetic landscape of\n                    <jats:italic>CFTR<\/jats:italic>\n                    gene variants in Russian patients, showcasing a diverse spectrum with a predominance of severe variants, some of which are rare and distinct from global populations. A total of 233 variants have been documented, exhibiting frequencies ranging from 0.01% to 51.5%, with 47 of these variants remaining uncharted within international genetic databases. As of 2021, CFTR modulator therapy has been introduced for patients under 19 years, heightening the importance of genetic diagnosis. In 2023, more than 1,850 patients under 19 received CFTR modulator therapy. Notably, the impact of complex alleles on disease progression and response to targeted therapies is gaining recognition. Comparisons with European registries highlight distinctive features of the Russian population, such as differences in age distribution among patients. Additionally, the study emphasizes the need to ascertain clinical significance and pathogenicity of newly identified genetic variants, along with exploring their suitability for targeted therapies. The integration of genetic insights into the management of CF offers potential for enhanced personalized therapeutic interventions. In conclusion, this thorough analysis provides a comprehensive understanding of the genetic nuances within the Russian CF population. By illuminating the intricate relationship between genetic variations and disease manifestation, the study underscores the essential role of genetics in shaping therapeutic strategies and improving patient outcomes. Further research and ongoing genetic exploration are crucial for optimizing the care of individuals with CF in the era of evolving therapeutic options.\n                  <\/jats:p>","DOI":"10.3389\/fgene.2024.1383033","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:47:14Z","timestamp":1730076434000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Study of the genetic and molecular epidemiology of cystic fibrosis based on the patient registry for planning targeted therapy in Russian Federation"],"prefix":"10.3389","volume":"15","author":[{"given":"Elena","family":"Kondratyeva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliya","family":"Melyanovskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoriya","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Voronkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Zhekaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislav","family":"Krasovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Amelina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliya","family":"Kashirskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Shadrina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Polyakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tagui","family":"Adyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"S\u0441hagina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Starinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Enina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Vasilyev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Marakhonov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rena","family":"Zinchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Kutsev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.18093\/0869-0189-2021-31-2-167-177","article-title":"Functional tests for assessment of residual CFTR channel activity and personalized selection of efficacious CFTR-modulators for cystic fibrosis patients with \u2018mild\u2019 and \u2018severe\u2019 genetic variants","volume":"31","author":"Amelina","year":"2021","journal-title":"PULMONOLOGIYA"},{"key":"B2","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/humu.23389","article-title":"Cis variants identified in F508del complex alleles modulate CFTR channel rescue by small molecules","volume":"39","author":"Baatallah","year":"2018","journal-title":"Hum. Mutat."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2202437","DOI":"10.1183\/13993003.02437-2022","article-title":"The French Compassionate Program of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant","author":"Burgel","year":"2023","journal-title":"Eur. Respir. J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"ECFS best practice guidelines: the 2018 revision","volume":"17","author":"Castellani","year":"2018","journal-title":"J. Cyst. Fibros. official J. Eur. Cyst. Fibros. Soc."},{"key":"B5","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1016\/s1569-1993(23)00452-6","article-title":"P077 Clinical and functional efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis carrying the N1303K mutation","author":"Cohen-Cymberknoh","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"B6","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jcf.2018.05.011","article-title":"Physiological and pharmacological characterization of the N1303K mutant CFTR","volume":"17","author":"DeStefano","year":"2018","journal-title":"J. Cyst. Fibros. official J. Eur. Cyst. Fibros. Soc."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2300110","DOI":"10.1183\/13993003.00110-2023","article-title":"Theratyping cystic fibrosis patients to guide elexacaftor\/tezacaftor\/ivacaftor out-of-label prescription","volume":"62","author":"Dreano","year":"2023","journal-title":"Eur. Respir. J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"00716-2021","DOI":"10.1183\/23120541.00716-2021","article-title":"Novel CFTR modulator combinations maximise rescue of G85E and N1303K in rectal organoids","volume":"8","author":"Ensinck","year":"2022","journal-title":"ERJ open Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1002\/ppul.20920","article-title":"Incidence of cystic fibrosis in the Albanian population","volume":"43","author":"Festini","year":"2008","journal-title":"Pediatr. Pulmonol."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-1993(23)00453-8","article-title":"P078 Case report: elexacaftor\/tezacaftor\/ivacaftor as a game changer in an individual with CFTR class II mutation N1303k","volume":"87","author":"Gona-Hoepler","year":"2023","journal-title":"J. Cyst. Fibros. 22S2. S."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1056\/NEJMra2216474","article-title":"Cystic fibrosis","volume":"389","author":"Grasemann","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B12","volume-title":"Monograph cystic fibrosis: 2nd edition revised and supplemented","author":"Kashirskaya","year":"2021"},{"key":"B13","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/BF00207378","article-title":"Highly variable incidence of cystic fibrosis and different mutation distribution among different Jewish ethnic groups in Israel","volume":"96","author":"Kerem","year":"1995","journal-title":"Hum. Genet."},{"key":"B14","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3390\/genes12060837","article-title":"Health characteristics of patients with cystic fibrosis whose genotype includes a variant of the nucleotide sequence c.3140-16t>A and functional analysis of this variant","volume":"12","author":"Kondratyeva","year":"2021","journal-title":"Genes"},{"key":"B15","doi-asserted-by":"publisher","first-page":"5126","DOI":"10.3390\/cimb44100349","article-title":"Personalized Selection of a CFTR Modulator for a Patient with a Complex Allele [L467F;F508del]","volume":"44","author":"Kondratyeva","year":"","journal-title":"Curr. issues Mol. Biol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"145023","DOI":"10.1016\/j.gene.2020.145023","article-title":"Clinical and genetic characterization of patients with cystic fibrosis and functional assessment of the chloride channel with the pathogenic variant c.831G>A (p.Trp277*), described for the first time","volume":"761","author":"Kondratyeva","year":"2020","journal-title":"Gene"},{"key":"B17","doi-asserted-by":"publisher","first-page":"10377","DOI":"10.3390\/ijms231810377","article-title":"Evaluation of the Complex p.[Leu467Phe;Phe508del] CFTR Allele in the Intestinal Organoids Model: Implications for Therapy","volume":"23","author":"Kondratyeva","year":"","journal-title":"Int. J. Mol. Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"6351","DOI":"10.3390\/ijms24076351","article-title":"Clinical and functional characteristics of the E92K CFTR gene variant in the Russian and Turkish population of people with cystic fibrosis","volume":"24","author":"Kondratyeva","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"60","DOI":"10.25557\/2073-7998.2024.01.60-68","article-title":"Study of a rare variant of the CFTR c.1329_1350del gene in a homozygous state in a child with cystic fibrosis using functional tests","volume":"23","author":"Kondratyeva","year":"2024","journal-title":"Med. Genet."},{"key":"B20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.25557\/2073-7998.2019.09.9-18","article-title":"Clinical and genetic features of cystic fibrosis patients with novel pathogenic variant CFTR c.1083G> A (p.Trp361*) and functional assessment of the activity of the chloride channel","volume":"18","author":"Kondratyeva","year":"2019","journal-title":"Med. Genet."},{"key":"B21","doi-asserted-by":"publisher","first-page":"233","DOI":"10.18093\/0869-0189-2023-33-2-233-242","article-title":"Description of the clinical picture and assessment of functional activity of the CFTR channel in a patient with a complex allele [S466X; R1070Q]","volume":"33","author":"Krasnova","year":"2023","journal-title":"PULMONOLOGIYA"},{"key":"B22","first-page":"95","volume-title":"Russian federation cystic fibrosis patient registry","author":"Krasovsky","year":"2021"},{"key":"B23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41572-024-00538-6","article-title":"Cystic fibrosis","volume":"10","author":"Mall","year":"2024","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B24","doi-asserted-by":"publisher","first-page":"S308","DOI":"10.1016\/s1569-1993(21)02073-7","article-title":"650: clinical and genetic characteristics of a patient with a newly described pathogenic variant CFTR p.Asn505His c.1513A >C p.(Asn505His) de novo and functional assessment of the chloride channel","volume":"20","author":"Melyanovskaya","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"B25","doi-asserted-by":"publisher","first-page":"170","DOI":"10.14300\/mnnc.2020.15041","article-title":"Course of the disease with evaluation of the chloride channel function and selection of target therapy in vitro in an adult with cystic fibrosis with 2184insa\/l138ins genotype","volume":"15","author":"Melyanovskaya","year":"2020","journal-title":"Med. News North Cauc."},{"key":"B26","unstructured":"Clinical guidelines for cystic fibrosis2021"},{"key":"B27","unstructured":"ECFSPR annual report 2020\n            OrentiA.\n            ZolinA.\n            JungA.\n            van RensJ.\n            FoxA.\n            KrasnykM.\n          2022"},{"key":"B28","doi-asserted-by":"publisher","first-page":"678374","DOI":"10.3389\/fgene.2021.678374","article-title":"Ethnic differences in the frequency of CFTR gene mutations in populations of the European and North Caucasian part of the Russian federation","volume":"12","author":"Petrova","year":"2021","journal-title":"Front. Genet."},{"key":"B29","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12881-019-0785-z","article-title":"Spectrum of CFTR mutations in Chechen cystic fibrosis patients: high frequency of c.1545_1546delTA (p.Tyr515X; 1677delTA) and c.274G>A (p.Glu92Lys, E92K) mutations in North Caucasus","volume":"20","author":"Petrova","year":"2019","journal-title":"BMC Med. Genet."},{"key":"B30","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12864-022-08466-z","article-title":"High frequency of complex CFTR alleles associated with c.1521_1523delCTT (F508del) in Russian cystic fibrosis patients","volume":"23","author":"Petrova","year":"2022","journal-title":"BMC genomics"},{"key":"B31","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3390\/genes11050554","article-title":"Analysis of CFTR mutation spectrum in ethnic Russian cystic fibrosis patients","volume":"11","author":"Petrova","year":"2020","journal-title":"Genes"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1016\/j.jcf.2016.02.003","article-title":"High prevalence of W1282x mutation in cystic fibrosis patients from Karachay-Cherkessia","volume":"15","author":"Petrova","year":"2016","journal-title":"J. Cyst. Fibros. official J. Eur. Cyst. Fibros. Soc."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.jcf.2023.06.001","article-title":"Clinical and functional efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis carrying the N1303K mutation","volume":"22","author":"Sadras","year":"2023","journal-title":"J. Cyst. Fibros. official J. Eur. Cyst. Fibros. Soc."},{"key":"B34","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.3390\/ijms23063175","article-title":"The L467F-F508del Complex Allele Hampers Pharmacological Rescue of Mutant CFTR by Elexacaftor\/Tezacaftor\/Ivacaftor in Cystic Fibrosis Patients: The Value of the ex vivo Nasal Epithelial Model to Address Non-Responders to CFTR-Modulating Drugs","volume":"23","author":"Sondo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B35","article-title":"The molecular genetic epidemiology of cystic fibrosis. Report of a Joint Meeting of WHO\/ECFTN\/ICF(M)\/ECFS. Genoa, Italy, 19 June 2002","year":"2004","journal-title":"Hum. Genet. Program"}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2024.1383033\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:47:17Z","timestamp":1730076437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2024.1383033\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":35,"alternative-id":["10.3389\/fgene.2024.1383033"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2024.1383033","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,28]]},"article-number":"1383033"}}